Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.30 |
| ▸ | GABRD | O14764 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.30 |
| ▸ | GABRE | P78334 | 1/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29378242 | 0.81 | SMN1; SMN2 (0.50) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| SCHEMBL56617 | 0.81 | SMN1; SMN2 (0.50) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| Hydrochloric Acid SCHEMBL2523036 | 0.79 | SMN1; SMN2 (0.48) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| Water SCHEMBL28081708 | 0.79 | SMN1; SMN2 (0.48) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| Dimethylamine SCHEMBL31596354 | 0.74 | SMN1; SMN2 (0.44) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| Nitrous Acid SCHEMBL27924301 | 0.74 | SMN1; SMN2 (0.44) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| SCHEMBL7427927 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2LMNANAPRTEGFRALDH1A1 | |
| SCHEMBL29375536 | 0.72 | SLC6A12 (0.38) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| SCHEMBL671978 | 0.72 | SLC6A12 (0.38) | SLC6A12SMN1; SMN2LMNAKEAP1NFE2L2 | |
| SCHEMBL1571548 | 0.72 | EGFR (0.35) | SLC6A12SMN1; SMN2EGFRGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2022-10-18 | — | — | US | disclosed |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-03-24 | — | — | US | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-08-08 | — | — | US | disclosed |
| EP-3512849-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | Bayer Aktiengesellschaft (DE) | 2019-07-24 | — | — | EP | disclosed |
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241562-A1 | 7-SUBSTITUTED 1-PYRIDYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | GLS, TNNI3, AADAC | SLC6A12 3951/4885SMN1; SMN2 2225/4885LMNA 210/4885 |
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | CHRM2, CHRM1, CHRM3 | SLC6A12 1653/4885SMN1; SMN2 4043/4885LMNA 4169/4885 |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | SLC6A12 4086/4885SMN1; SMN2 2441/4885LMNA 310/4885 |
| US-20220089591-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | SLC6A12 4086/4885SMN1; SMN2 2441/4885LMNA 310/4885 |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | SLC6A12 1653/4885SMN1; SMN2 4043/4885LMNA 4169/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | SLC6A12 4086/4885SMN1; SMN2 2441/4885LMNA 310/4885 |
| US-11472803-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | SLC6A12 4086/4885SMN1; SMN2 2441/4885LMNA 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.